Clinical Trial Update: Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 randomized trial comparing pazopanib to sunitinib in first-line locally advanced or metastatic renal cell carcinoma has completed, with results posted i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Pazopanib (Pazopanib)
• Sunitinib (sunitinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Carcinoma, Renal Cell | Phase 3 | Status: COMPLETED | Results posted: 2013-06-17